Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: Toronto
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Trimel Pharmaceuticals Corp

+ Add to Watchlist


0.7000 CAD 0.0300 4.48%

As of 13:54:37 ET on 05/22/2015.

Snapshot for Trimel Pharmaceuticals Corp (TRL)

Open: 0.6700 Day's Range: 0.6700 - 0.7100 Volume: 212,400
Previous Close: 0.6700 52wk Range: 0.3100 - 0.9200 1-Yr Rtn: -1.41%

Stock Chart for TRL

No chart data available.
  • TRL:CN 0.7000
  • 1D
  • 1M
  • 1Y
Interactive TRL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TRL

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPTSX -
Earnings Per Share (USD) (ttm) -0.0997
Est. EPS (USD) (12/2015) -0.0250
Est. PEG Ratio -
Market Cap (M CAD) 140.61
Shares Outstanding (M) 200.87
30 Day Average Volume 95,515
Price/Book (mrq) 10.4465
Price/Sale (ttm) 14.8998
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TRL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for TRL

Trimel Pharmaceuticals Corp. is a pharmaceutical development company. The Company's primary objective is to exploit Trimel's drug-delivery technology portfolio and to target unmet medical needs in underserved disease states. Trimel's term objectives include the development of products for the treatment of male hypogonadism, female sexual dysfunction, and Parkinson's disease.

Tom RossiPresident/CEOKenneth G HowlingChief Financial Officer
Hubert CzerwinskiPres:Trimel Biopharma SRLNathan John BrysonVP:Scientific Affairs
More Company Profile & Key Executives for TRL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil